VIVS: Organovo Holdings, Inc. EV/EBITDA Multiple

VivoSim Labs Inc (VIVS) minimizes environmental impact through precision analyses that reduce chemical waste. VivoSim Labs Inc generates revenue by supplying bioprinted structures to pharma behemoths, enabling drug testing without the use of animals. The company's price evolution, featuring the 0.00 metric, reflects the business valuation dynamics. Additionally, the brand promotes ethical bioprinting by optimizing energy consumption and medical waste disposal within its laboratories.

organovo.com - VIVS Enterprise Value to EBITDA Ratio (period 11/23/2025 - 11/12/2026)

Summary analytical data breakdowns for Organovo Holdings (VIVS)

- stock price and consensus target price:

Stock Quotes organovo.com|VIVS - Analyst Forecast Prices

- market capitalization information:

Market Capitalization VivoSim Labs|VIVS - Company Buyout Price

- issuer book value statistics:

Book Value per Share Organovo|VIVS - Company Net Assets|Market Cap to Net Assets Ratio organovo.com|VIVS - Aggregate Asset Value

- company liabilities and liquidity data:

- financial results and valuation multiples details:

VIVS - Net Income|Projected Future Earnings VivoSim Labs Inc|VIVS - P/E Multiple|Future Price to Earnings VivoSim Labs Inc|VIVS - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio VivoSim Labs|VIVS - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Organovo|VIVS - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months organovo.com|VIVS - Net earnings per share change in current year|Expected earnings per share growth for next year VivoSim Labs Inc

Initial company analysis:VivoSim Labs VIVS

This metric compares the total enterprise value of VivoSim Labs Inc (VIVS) including debt to its earnings before interest, taxes, depreciation, and amortization. By analyzing fluctuations in the company's EV/EBITDA ratio, an investor determines the degree of asset overvaluation and the business's ability to service its debt load. Current price action reflects risks of declining efficiency due to geopolitical restrictions hindering the supply of bioprinters and the expansion of the laboratory network.

Competitor analysis for VivoSim Labs Inc

Abbott Laboratories Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio TMO (Thermo Scientific)|GE HealthCare - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio mt.com MTD|WAT: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Bio-Techne Corp|Enterprise Value to EBITDA Ratio BRKR|AZTA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Varex Imaging (VREX)|Enterprise Value to EBITDA Ratio semlerscientific.com SMLR|EV/EBITDA Multiple BFLY (Butterfly Network)|Mesa Laboratories Inc (MLAB) - Company Value to EBITDA|Quantum-Si Corp - EV/EBITDA Multiple|NNOX (Nano-X Imaging Ltd) - Enterprise Value to Operating Income Before Depreciation|QTRX: EV/EBITDA Multiple|MASS - Total Company Value to Operating Income Before Depreciation Ratio|CV (CapsoVision, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio MaxCyte Inc. (MXCT)|EV/EBITDA Multiple RPID|EV/EBITDA Multiple Seer Bio (SEER)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Hyperfine, Inc. HYPR|fonar.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|DXR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation MDAI (spectral-ai.com)|ACON: EV/EBITDA Multiple|Company Value to EBITDA Akoya Biosciences, Inc. (AKYA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ThermoGenesis|TLIS - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio TTOO (T2 Biosystems)